Company: CPMV
Filing Date: 2025-08-19
Form Type: 10-Q
Source: 0001683168-25-006318
Chunk: 1

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-08-19
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
,073 
  
    Accumulated deficit 
     (9,191,668) 
     (8,838,320)
  
    Total stockholders’ deficit 
     (7,141,522) 
     (6,788,174)
  
    Total liabilities and stockholders’ deficit 
    $57,699  
    $141,611 

See accompanying notes to unaudited condensed consolidated
financial statements.

 4 

Mosaic ImmunoEngineering, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

    Three Months Ended  
    Six Months Ended 

    June 30, 2025  
    June 30, 2024  
    June 30, 2025  
    June 30, 2024 

    Operating expenses: 

    Research and development 
    $16,006  
    $60,707  
    $31,809  
    $128,018 
  
    General and administrative 
     132,848  
     213,595  
     291,819  
     415,050 
  
    Total operating expenses 
     148,854  
     274,302  
     323,628  
     543,068 

    Loss from operations 
     (148,854) 
     (274,302) 
     (323,628) 
     (543,068)

    Other income (expense): 

    Other income 
     –  
     –  
     14,000  
     – 
  
    Interest income 
     1  
     1  
     4  
     4 
  
    Interest expense on loan payable 
     (2,493) 
     –  
     (4,959) 
     – 
  
    Non-cash interest expense on convertible notes 
     (18,282) 
     (19,416) 
     (36,365) 
     (37,699)
  
    Accretion to redemption value on convertible notes 
     –  
     –  
     –  
     (1,446)
  
    Total other income (expense), net 
     (20,774) 
     (19,415) 
     (27,320) 
     (